Menu
Recruiting NCT05605639

Phrenic Nerve Infiltration in Neck Pain

Phase IV Interventional Chronic Neck Pain

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Bupivacaine, Placebo (physiological saline serum infiltration).
Who it may be relevant to
Registry conditions: Chronic Neck Pain. Basic parameters: 18 years — 64 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Spain
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Phrenic Afferences In Organic and Metabolic Illness: Central Sensitization

Overview

Neck pain frequently present comorbidities in peridiaphragmatic organs. The innervation of these organs include the phrenic nerve. It is known that peridiaphragmatic organs trigger referred pain in the neck area. As well, previous studies have shown that visceral disorders increase sensitization in somatic tissues. This study aims to analyze the ability of phrenic nerve infiltration to diminish sensitization and improve neck symptoms in the absence of neurological, traumatic or infectious pathology that justifies the pain, by means of a randomized controlled trial.

Detailed description

Pain is a major problem due to issues such as the impact on quality of life and the associated health and social costs. Neck pain is a very common disorder in our society. It is characterized by the presence of hyperalgesia, increased muscle tone, limited range of motion and sensitization. It is well known that pain of visceral origin can generate all these phenomena. In most cases, there is no antecedent of trauma, and no evidence of a specific origin (oncologic, rheumatic, infectious…), so patients are classified as suffering non-specific or idiopathic pain. The absence of a specific diagnosis makes it difficult to find a therapeutic target to increase the probability of successful therapies. Thus, in the case of neck pain, the recurrence of consultations is very high.

It is known that cervical pain frequently presents peridiaphragmatic visceral comorbidities. Furthermore, it is known that these peridiaphragmatic organs produce referred pain to the neck, and this pain is known as phrenic pain. To date, there are no studies that analyze the role of phrenic afferents in subjects with neck pain and peridiaphragmatic visceral disorders. The aim of this study is to evaluate the effect of phrenic nerve anaesthesia in subjects with neck pain. For this purpose, the investigators intend to perform a randomised clinical trial, assessing the effects on pain threshold to pressure, visual analogue scale, range of motion and craniocervical questionnaires. There will be only one intervention session. The experimental group will receive an ultrasound-guided anaesthetic infiltration of the phrenic nerve, while the control group will receive a placebo infiltration. A one-week follow-up, with intermediate measurements, will be carried out to assess the evolution of cervical sensitization and symptomatology.

The results of this study will make it possible to establish the role of peridiaphragmatic organic disorders and phrenic afferents in cervical pain, thus making it possible to specify a specific therapeutic target (phrenic nerve) as well as the importance of visceral treatment in subjects presenting for consultation for cervical pain.

Interventions

  • Drug Bupivacaine
    The experimental intervention will consist of ultrasound-guided anesthetic blockade of the phrenic nerve at the laterocervical supraclavicular level with 1 ml of lidocaine without vasoconstrictor 2% to infiltrate the skin and 3ml of bupivacaine without vasoconstrictor 0.25% for neural blockade, making the local anesthetic surround the nerve between the anterior scalene muscle and the sternocleidomastoid muscle.
  • Other Placebo (physiological saline serum infiltration)
    The placebo intervention will be similar in relation to 2% lidocaine without vasoconstrictor for the skin, but an ultrasound-guided puncture will be performed at the level of the subcutaneous cellular tissue by injecting 3 ml of physiological saline.

Primary outcome measures

  • Change from baseline in algometry [Time frame: Pre-intervention. Post-intervention: 1 hour, 2 hours, 3 days and 7 days]
Secondary outcome measures (4)
  • Range of motion [Time frame: Pre-intervention. Post-intervention: 1 hour, 2 hours, 3 days and 7 days]
  • Visual Analogue Scale [Time frame: Pre-intervention. Post-intervention: 1 hour, 2 hours, 3 hours, 6 hours, 24 hours, 2 days, 3 days and 7 days]
  • Neck Disability Index [Time frame: Pre-intervention. Post-Intervention: 3 days and 7 days.]
  • Headache Impact Test-6 [Time frame: Pre-intervention. Post-intervention: 3 days and 7 days.]

Eligibility criteria

Inclusion criteria

  • Over 18 and under 64 years old
  • Patients attending to the physician or physical therapist with a main complaint of neck pain
  • Presentation of any peridiaphragmatic visceral disorder.
  • That the subject agrees to participate in the project by signing the informed consent.

Exclusion criteria

  • Illness of neurological, traumatic, oncological, infectious or rheumatic (fibromyalgia, ankylosing spondylitis...) origin.
  • Uncooperative subject.
  • Severe psychiatric illness.
  • Loss of Cognitive Ability.
  • Contraindication to infiltration of the phrenic nerve.
  • History of head, spinal or upper limb surgery
  • History of infiltration for the neck pain in the previous 3 months
  • History of physical therapy for the neck pain in the previous 30 days

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Triple blind
Primary purpose
Treatment

Study locations

Spain · 2 centers
  • Nacho Navarro Fisioterapia — Dos Hermanas
  • Crux Roxa — Seville

Identifiers

NCT: NCT05605639 · 0746-N-21

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗